Cure My Disease

Don't miss your cure!

 Log in / Sign up

New RA drug trial halted early – what we know

NCT ID NCT06859294

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called LY3541860 in 35 adults with moderate-to-severe rheumatoid arthritis who had not improved enough on other treatments. The goal was to see if the drug could reduce joint swelling and pain. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY3541860 (given intravenously)
What this could lead to
If successful, this could point toward a new treatment option for people with rheumatoid arthritis who haven't responded well to other therapies.
What could go wrong
The trial was terminated early and only enrolled 35 people, so results are limited. It is still early-stage research, and the drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

35 people

The number who actually took part.

Started

Mar 2025

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria. * Have moderately to severely active RA, at screening (Visit 1) and baseline (Visit 2), defined by the presence of * ≥6 swollen joints based on 66 joint count (and ≥4 swollen joints on 28 joint count), and * ≥6 tender joints based on 68 joint count (and ≥4 tender joints on 28 joint count). * Have active synovitis in ≥1 joint, in hands or wrists, of the investigator choosing at screening, having an MRI synovitis RAMRIS score of ≥2 as determined from the central reading of the images. Exclusion Criteria: * Have a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of * basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline. * Have estimated glomerular filtration rate (eGFR) of \<45 milliliter per minute (mL/minute) from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. * Have a current or recent active infection. * Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to * poorly controlled diabetes or hypertension * chronic kidney disease Stage 3a or b, 4, or 5 * symptomatic heart failure according to New York Heart Association Class 2, 3, or 4 * myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before baseline * severe chronic pulmonary disease, for example, requiring oxygen therapy major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to * systemic lupus erythematosus * psoriatic arthritis * axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis * reactive arthritis * gout * scleroderma * polymyositis * dermatomyositis * active fibromyalgia, or * multiple sclerosis * Have received any prior B-cell targeted therapy (for example, anti-CD19 antibodies or anti-CD20 antibodies, such as rituximab). * Received corticosteroids, opioids, conventional disease-modifying antirheumatic drug (cDMARD), with changes in dose or have received Janus kinase (JAK) inhibitors within 28 days prior to the screening MRI or plan on receiving these drugs during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale

    Avondale, Arizona, 85392, United States

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff

    Flagstaff, Arizona, 86001, United States

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa

    Mesa, Arizona, 85210, United States

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV

    Phoenix, Arizona, 85032, United States

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City

    Sun City, Arizona, 85351, United States

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast

    Tucson, Arizona, 85748, United States

  • Accurate Clinical Management, LLC

    Baytown, Texas, 77521, United States

  • Accurate Clinical Research, Inc

    Lake Charles, Louisiana, 70605, United States

  • Accurate Clinical Research, Inc

    Houston, Texas, 77089, United States

  • Altoona Center For Clinical Research

    Duncansville, Pennsylvania, 16635, United States

  • Clinical Research of West Florida

    Tampa, Florida, 33606, United States

  • Clinical Research of West Florida, Inc. (Clearwater)

    Clearwater, Florida, 33765, United States

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • DM Clinical Research - TRA

    Tomball, Texas, 77375, United States

  • Medvin Clinical Research - Covina

    Covina, California, 91722, United States

  • Medvin Clinical Research - Tujunga

    Tujunga, California, 91042, United States

  • Medvin Clinical Research - Whittier

    Whittier, California, 90602, United States

  • Newport Huntington Medical Group

    Huntington Beach, California, 92648, United States

  • Saint Paul Rheumatology

    Eagan, Minnesota, 55121, United States

  • Willow Rheumatology and Wellness PLLC

    Willowbrook, Illinois, 60527, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.